Bioventus

US · BVS #3345 by market cap Listed 2021

12.77 -0.33 -2.52%

Live - 5344 symbols - heartbeat 221s ago · 2026-10-08 08:44

Pre-market 12.75 -0.16%

After-hours 12.77 0.00%

Market cap: 872.26M
P/E (TTM): 16.37
P/B: 3.82
EPS: 0.33
Div yield: 0.00%
52W pos: 67%

Reader sentiment Are you bullish or bearish on BVS?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Weak

Altman Z-Score is 1.76, below the 1.8 "distress zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year -0.91% YoY

Margins

Gross margin: 68.33%
Operating margin: 9.91%
Net margin: 4.00%

Key ratios & quality

Enterprise value: 1.11B
Altman Z-Score: 1.76

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	319.18M	340.14M	321.16M	430.90M	512.12M	512.35M	573.28M	568.09M
Gross profit	235.01M	249.21M	233.52M	302.71M	331.08M	328.19M	388.23M	388.16M
Selling & admin expenses	191.67M	198.48M	193.08M	254.25M	332.13M	303.88M	343.80M	314.03M
Research & development	8.10M	11.06M	11.20M	19.04M	23.85M	13.45M	13.95M	12.11M
Operating profit	27.37M	31.77M	21.80M	21.05M	-34.66M	2.03M	22.83M	56.29M
Pretax profit	6.11M	9.69M	15.91M	9.49M	-189.03M	-121.11M	-52.34M	25.71M
Tax	1.66M	1.58M	1.19M	-1.97M	-44.37M	85.00K	-5.29M	-1.57M
Net profit	-12.21M	6.30M	14.72M	9.59M	-213.39M	-195.63M	-47.05M	27.27M
Basic EPS	0	0	0	0	-3	-2	-1	0
Diluted EPS	-0.22	0.12	0.44	-0.15	-2.59	-2.49	-0.56	0.33

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	123.88M	147.66M	138.65M	157.90M	132.09M	153.21M
Gross profit	83.06M	102.09M	94.23M	108.78M	90.77M	105.67M
Selling & admin expenses	73.50M	79.11M	78.66M	82.76M	78.33M	82.74M
Research & development	3.01M	3.17M	2.92M	3.01M	2.47M	3.17M
Operating profit	4.95M	18.37M	11.25M	21.72M	8.87M	18.71M
Pretax profit	-3.42M	10.31M	4.67M	14.14M	4.52M	15.31M
Tax	-95.00K	1.04M	664.00K	-3.18M	571.00K	-20.90M
Net profit	-3.32M	9.27M	4.01M	17.32M	3.95M	36.21M
Basic EPS	0	0	0	0	0	0
Diluted EPS	-0.04	0.11	0.05	0.21	0.04	0.47

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	148.35M	183.03M	211.79M	263.10M	272.58M	268.00M	275.61M	272.84M
Cash & ST investments	42.77M	64.52M	86.84M	43.93M	30.19M	36.96M	41.58M	51.24M
Inventory	27.40M	27.33M	29.12M	61.69M	84.77M	91.33M	92.48M	82.24M
Total assets	442.72M	472.41M	494.47M	1.23B	1.37B	810.91M	727.96M	683.56M
Total current liabilities	65.43M	89.02M	122.59M	180.86M	304.02M	175.50M	210.40M	160.38M
Short-term debt	5.25M	10.00M	15.00M	18.04M	33.06M	27.85M	27.34M	15.00M
Long-term debt	189.58M	187.97M	173.38M	339.64M	385.01M	367.00M	308.29M	278.95M
Total liabilities	297,456,000.00	326,790,000.00	350,306,000.00	692,073,000.00	960,427,000.00	589,792,000.00	542,352,000.00	455,112,000.00
Total equity	145.27M	145.62M	144.16M	533.79M	412.22M	221.12M	185.60M	228.45M
Retained earnings	-139.82M	-141.70M	0	-6.60M	-165.31M	-321.54M	-357.66M	-334.93M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	249.37M	275.20M	280.90M	272.84M	249.81M	257.53M
Cash & ST investments	22.80M	32.91M	42.16M	51.24M	35.85M	29.46M
Inventory	94.05M	96.47M	96.27M	82.24M	83.19M	79.81M
Total assets	691.41M	706.79M	701.59M	683.56M	650.54M	673.35M
Total current liabilities	174.75M	185.68M	161.75M	160.38M	148.10M	152.45M
Short-term debt	41.70M	43.36M	11.25M	15.00M	18.75M	18.75M
Long-term debt	308.59M	297.88M	311.33M	278.95M	253.33M	229.70M
Total liabilities	505,935,000.00	505,489,000.00	494,338,000.00	455,112,000.00	416,274,000.00	395,934,000.00
Total equity	185.48M	201.30M	207.26M	228.45M	234.27M	277.41M
Retained earnings	-360.30M	-352.84M	-349.68M	-334.93M	-331.82M	-298.38M

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	45.19M	40.71M	71.80M	22.99M	-13.54M	15.34M	38.80M	74.67M
Depreciation & amortization	29.24M	30.32M	28.64M	34.88M	55.40M	57.37M	49.56M	47.01M
Free cash flow	39.13M	32.37M	51.13M	2.10M	-15.02M	7.98M	37.79M	72.11M
Dividends paid	-7.85M	-9.14M	-19.89M	--	--	--	--	--
Stock buybacks / issuance	--	0	0	109.41M	5.82M	778.00K	2.44M	2.07M
Ending cash balance	42.77M	64.52M	86.84M	99.21M	31.84M	36.96M	41.58M	51.24M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	-19.33M	25.94M	30.10M	37.97M	8.93M	19.87M
Depreciation & amortization	11.87M	12.05M	11.40M	11.69M	11.21M	10.95M
Free cash flow	-20.16M	25.26M	29.63M	37.39M	8.36M	18.91M
Dividends paid	--	--	--	--	--	--
Stock buybacks / issuance	150.00K	1.32M	96.00K	511.00K	120.00K	853.00K
Ending cash balance	22.80M	32.91M	42.16M	51.24M	35.85M	29.46M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	-8.40	4.75	11.51	6.45	-40.93	-63.75	-20.86	13.69
ROA %	-2.76	1.50	3.39	2.25	-12.22	-14.31	-4.36	3.22
ROIC %	0.51	7.32	7.57	3.52	-17.77	-19.34	0.20	8.83
5-year avg ROE %	--	--	--	--	-5.25	-16.10	-21.55	-21.09
EBIT margin %	7.92	9.19	7.99	2.03	-46.49	-15.70	-1.80	9.19
FCF / sales %	12.26	9.52	15.92	0.49	--	1.56	6.59	12.69
Current ratio	2.27	2.06	1.73	1.45	0.90	1.53	1.31	1.70
Quick ratio	1.76	1.68	1.43	0.93	0.55	0.91	0.80	1.12
Debt / assets	44.01	41.91	38.10	29.18	30.46	48.69	46.11	43.00
LT debt / equity	130.50	131.46	120.27	74.01	118.38	211.42	208.39	151.52
Interest coverage	1.32	1.45	2.63	7.85	-9.23	-1.98	-0.27	1.97
Revenue CAGR (3Y) %	7.96	6.96	4.83	10.52	14.61	16.85	9.98	3.52
Net income CAGR (3Y) %	--	--	--	--	--	--	--	--
FCF CAGR (3Y) %	50.50	--	34.78	-62.27	--	-46.15	162.01	--

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	-19.59	1.19	6.46	13.69	16.90	27.96
ROA %	-4.21	0.25	1.38	3.22	4.24	7.89
ROIC %	-0.03	5.17	7.04	8.83	8.71	13.56
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	-1.96	6.79	7.96	9.19	9.88	10.06
FCF / sales %	4.21	6.04	9.48	12.69	17.46	16.20
Current ratio	1.43	1.48	1.74	1.70	1.69	1.69
Quick ratio	0.81	0.89	1.07	1.12	1.06	1.10
Debt / assets	52.95	48.28	45.98	43.00	41.82	36.90
LT debt / equity	219.00	184.74	187.44	151.52	134.11	100.61
Interest coverage	-0.31	1.14	1.49	1.97	2.44	2.94
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

Pain Treatments is the largest reported line at 53.36% of revenue, across 3 reported segments.
Surgical Solutions follows at 32.87%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

Pain Treatments53.36%

Surgical Solutions32.87%

Restorative Therapies13.78%

Quote time 2026-10-08 08:44:52 · For reference only, not investment advice and not tailored to your situation.